| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:872.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Department of Internal Medicine, Graduate School of Medicine, University of Tokyo (T.O., T.A., K.A., Y.C., N.S., M.F., H.K., Y.F., T.F.), Tokyo; The Institute for Adult Diseases, Asahi Life Foundation (T.O., H.S., M.A., H.O., Y.O., M.K.), Tokyo; Research Center for Advanced Science and Technology, University of Tokyo (N.N., H.A.), Tokyo; and Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine (I.K.), Chiba, Japan.
Correspondence to Tomoichiro Asano, Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. E-mail asano-tky{at}umin.ac.jp
Angiotensin II (AII) is involved in the pathogenesis of both hypertension and insulin resistance, though few studies have examined the relationship between the two. We therefore investigated the effects of chronic AII infusion on blood pressure and insulin sensitivity in rats fed a normal (0.3% NaCl) or high-salt (8% NaCl) diet. AII infusion for 12 days significantly elevated blood pressure and significant insulin resistance, assessed by a hyperinsulinemic-euglycemic clamp study and glucose uptake into isolated muscle and adipocytes. High-salt loading exacerbated the effects of AII infusion significantly. Despite the insulin resistance, insulin-induced tyrosine phosphorylation of the insulin receptor and insulin receptor substrates, activation of phosphatidylinositol (PI) 3-kinase, and phosphorylation of Akt were all enhanced by AII infusion. Subsequently, to investigate whether oxidative stress induced by AII contributes to insulin resistance, the membrane-permeable superoxide dismutase mimetic, tempol, was administered to AII-infused rats. Chronic AII infusion induced an accumulated plasma cholesterylester hydroperoxide levels, indicating the increased oxidative stress, whereas the treatment with tempol normalized plasma cholesterylester hydroperoxide levels in AII-infused rats. In addition, the treatment with tempol normalized insulin resistance in AII-infused rats, shown as a decreased glucose infusion rate in the hyperinsulinemic euglycemic clamp study and a decreased insulin-induced glucose uptake into isolated skeletal muscle, as well as enhanced insulin-induced PI 3-kinase activation to those in the control rats. These results strongly suggest that AII-induced insulin resistance cannot be attributed to impairment of early insulin-signaling steps and that increased oxidative stress, possibly through impaired insulin signaling located downstream from PI 3-kinase activation, is involved in AII-induced insulin resistance.
Key Words: angiotensin II insulin resistance oxidative stress glucose clamp technique sodium kinase
This article has been cited by other articles:
![]() |
D. Zhuang, Q. Pu, B. Ceacareanu, Y. Chang, M. Dixit, and A. Hassid Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H163 - H173. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, J. R. Sowers, S. E. Clark, W. Li, C. M. Ferrario, and C. S. Stump Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-{kappa}B activation via NADPH oxidase Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E345 - E351. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fujita Insulin resistance and salt-sensitive hypertension in metabolic syndrome Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3102 - 3107. [Full Text] [PDF] |
||||
![]() |
S. Tiwari, S. Riazi, and C. A. Ecelbarger Insulin's impact on renal sodium transport and blood pressure in health, obesity, and diabetes Am J Physiol Renal Physiol, October 1, 2007; 293(4): F974 - F984. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J. Henriksen Improvement of insulin sensitivity by antagonism of the renin-angiotensin system Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R974 - R980. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Jonk, A. J. H. M. Houben, R. T. de Jongh, E. H. Serne, N. C. Schaper, and C. D. A. Stehouwer Microvascular Dysfunction in Obesity: A Potential Mechanism in the Pathogenesis of Obesity-Associated Insulin Resistance and Hypertension Physiology, August 1, 2007; 22(4): 252 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Giani, M. M. Gironacci, M. C. Munoz, C. Pena, D. Turyn, and F. P. Dominici Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1154 - H1163. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-M. Jin and Y. Pan Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1943 - 1949. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. de Borst, S. H. Diks, J. Bolbrinker, M. W. Schellings, M. B. A. van Dalen, M. P. Peppelenbosch, R. Kreutz, Y. M. Pinto, G. Navis, and H. van Goor Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage Am J Physiol Renal Physiol, July 1, 2007; 293(1): F428 - F437. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Mehta and K. K. Griendling Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system Am J Physiol Cell Physiol, January 1, 2007; 292(1): C82 - C97. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Iwai, H.-S. Li, R. Chen, T. Shiuchi, L. Wu, L.-J. Min, J.-M. Li, M. Tsuda, J. Suzuki, Y. Tomono, et al. Calcium Channel Blocker Azelnidipine Reduces Glucose Intolerance in Diabetic Mice via Different Mechanism Than Angiotensin Receptor Blocker Olmesartan J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1081 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Imanishi, K. Kobayashi, A. Kuroi, S. Mochizuki, M. Goto, K. Yoshida, and T. Akasaka Effects of Angiotensin II on NO Bioavailability Evaluated Using a Catheter-Type NO Sensor Hypertension, December 1, 2006; 48(6): 1058 - 1065. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wei, J. R. Sowers, R. Nistala, H. Gong, G. M.-E. Uptergrove, S. E. Clark, E. M. Morris, N. Szary, C. Manrique, and C. S. Stump Angiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells J. Biol. Chem., November 17, 2006; 281(46): 35137 - 35146. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Boschmann, S. Engeli, F. Adams, G. Franke, F. C. Luft, A. M. Sharma, and J. Jordan Influences of AT1 receptor blockade on tissue metabolism in obese men Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2006; 290(1): R219 - R223. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Li, C. X Fang, N. S Aberle II, B. H Ren, A. F Ceylan-Isik, and J. Ren Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function J. Endocrinol., September 1, 2005; 186(3): 491 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Lemieux, C. J. Diehl, J. A. Sloniger, and E. J. Henriksen Voluntary exercise training enhances glucose transport but not insulin signaling capacity in muscle of hypertensive TG(mREN2)27 rats J Appl Physiol, July 1, 2005; 99(1): 357 - 362. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Taniyama, H. Hitomi, A. Shah, R. W. Alexander, and K. K. Griendling Mechanisms of Reactive Oxygen Species-Dependent Downregulation of Insulin Receptor Substrate-1 by Angiotensin II Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1142 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Sloniger, V. Saengsirisuwan, C. J. Diehl, B. B. Dokken, N. Lailerd, A. M. Lemieux, J. S. Kim, and E. J. Henriksen Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1074 - E1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-C. Juan, Y. Chien, L.-Y. Wu, W.-M. Yang, C.-L. Chang, Y.-H. Lai, P.-H. Ho, C. F. Kwok, and L.-T. Ho Angiotensin II Enhances Insulin Sensitivity in Vitro and in Vivo Endocrinology, May 1, 2005; 146(5): 2246 - 2254. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yvan-Charvet, P. Even, M. Bloch-Faure, M. Guerre-Millo, N. Moustaid-Moussa, P. Ferre, and A. Quignard-Boulange Deletion of the Angiotensin Type 2 Receptor (AT2R) Reduces Adipose Cell Size and Protects From Diet-Induced Obesity and Insulin Resistance Diabetes, April 1, 2005; 54(4): 991 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Morisco, G. Condorelli, V. Trimarco, A. Bellis, C. Marrone, G. Condorelli, J. Sadoshima, and B. Trimarco Akt Mediates the Cross-Talk Between {beta}-Adrenergic and Insulin Receptors in Neonatal Cardiomyocytes Circ. Res., February 4, 2005; 96(2): 180 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Blendea, D. Jacobs, C. S. Stump, S. I. McFarlane, C. Ogrin, G. Bahtyiar, S. Stas, P. Kumar, Q. Sha, C. M. Ferrario, et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E353 - E359. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Marrero, D. Fulton, D. Stepp, and D. M. Stern Angiotensin II-Induced Insulin Resistance and Protein Tyrosine Phosphatases Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2009 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ran, T. Hirano, and M. Adachi Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E955 - E961. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Xing, T. Shimosawa, T. Ogihara, H. Matsui, K. Itakura, X. Qingyou, T. Asano, K. Ando, and T. Fujita Angiotensin II-Induced Insulin Resistance Is Enhanced in Adrenomedullin-Deficient Mice Endocrinology, August 1, 2004; 145(8): 3647 - 3651. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ran, T. Hirano, and M. Adachi Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats Am J Physiol Endocrinol Metab, August 1, 2004; 287(2): E227 - E232. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Sowers Insulin resistance and hypertension Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1597 - H1602. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shiuchi, M. Iwai, H.-S. Li, L. Wu, L.-J. Min, J.-M. Li, M. Okumura, T.-X. Cui, and M. Horiuchi Angiotensin II Type-1 Receptor Blocker Valsartan Enhances Insulin Sensitivity in Skeletal Muscles of Diabetic Mice Hypertension, May 1, 2004; 43(5): 1003 - 1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sakoda, Y. Gotoh, H. Katagiri, M. Kurokawa, H. Ono, Y. Onishi, M. Anai, T. Ogihara, M. Fujishiro, Y. Fukushima, et al. Differing Roles of Akt and Serum- and Glucocorticoid-regulated Kinase in Glucose Metabolism, DNA Synthesis, and Oncogenic Activity J. Biol. Chem., July 3, 2003; 278(28): 25802 - 25807. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |